Our solution leverages breakthrough technology developed over 15 years at IRB, resulting in three families of shuttle peptides designed to traverse the Blood-Brain Barrier (BBB) through distinct mechanisms. Preclinical studies have revealed a 100-fold increase in brain penetration and notable reduction in tumor burden in DIPG xenograft models with intact BBB. Importantly, these studies have also demonstrated great tolerability of the therapy.